Tools
Tools
Akkerman, O W, Duarte, R, Tiberi, S, Schaaf, H S, Lange, C, Alffenaar, J W C, Denholm, J, Carvalho, A C C, Bolhuis, M S, Borisov, S, Bruchfeld, J, Cabibbe, A M, Caminero, J A, Carvalho, I, Muhwa, Jeremiah, Centis, R, Dalcomo, M P, D Ambrosio, L, Dedicoat, M, Dheda, K, Dooley, K E, Furin, J, García-García, J-M, van Hest, N A H, de Jong, B C, Kurhasani, X, Märtson, A G, Mpagama, S, Torrico, M Munoz, Nunes, E, Ong, C W M, Palmero, D J, Ruslami, R, Saktiawati, A M I, Semuto, C, Silva, D R, Singla, R, Solovic, I, Srivastava, S, de Steenwinkel, J E M, Story, A, Sturkenboom, M G G, Tadolini, M, Udwadia, Z F, Verhage, A R, Zellweger, J P and Migliori, G B (2022) 'Clinical standards for drug-susceptible pulmonary TB.'. International Journal of Tuberculosis and Lung Disease, Vol 26, Issue 7, pp. 592-604.
|
Text
s5-2.pdf - Published Version Available under License Creative Commons Attribution. Download (147kB) | Preview |
Abstract
The aim of these clinical standards is to provide guidance on 'best practice´ for diagnosis, treatment and management of drug-susceptible pulmonary TB (PTB). A panel of 54 global experts in the field of TB care, public health, microbiology, and pharmacology were identified; 46 participated in a Delphi process. A 5-point Likert scale was used to score draft standards. The final document represents the broad consensus and was approved by all 46 participants. Seven clinical standards were defined: Standard 1, all patients (adult or child) who have symptoms and signs compatible with PTB should undergo investigations to reach a diagnosis; Standard 2, adequate bacteriological tests should be conducted to exclude drug-resistant TB; Standard 3, an appropriate regimen recommended by WHO and national guidelines for the treatment of PTB should be identified; Standard 4, health education and counselling should be provided for each patient starting treatment; Standard 5, treatment monitoring should be conducted to assess adherence, follow patient progress, identify and manage adverse events, and detect development of resistance; Standard 6, a recommended series of patient examinations should be performed at the end of treatment; Standard 7, necessary public health actions should be conducted for each patient. We also identified priorities for future research into PTB. These consensus-based clinical standards will help to improve patient care by guiding clinicians and programme managers in planning and implementation of locally appropriate measures for optimal person-centred treatment for PTB.
| Item Type: | Article |
|---|---|
| Subjects: | WF Respiratory System > WF 20 Research (General) WF Respiratory System > Tuberculosis > WF 300 Pulmonary tuberculosis |
| Faculty: Department: | Clinical Sciences & International Health > Clinical Sciences Department |
| Digital Object Identifer (DOI): | https://doi.org/10.5588/ijtld.22.0228 |
| SWORD Depositor: | JISC Pubrouter |
| Depositing User: | JISC Pubrouter |
| Date Deposited: | 08 Dec 2022 13:03 |
| Last Modified: | 14 Jun 2023 11:46 |
| URI: | https://archive.lstmed.ac.uk/id/eprint/20792 |
Statistics
Actions (login required)
 |
Edit Item |